Skip to main content

10 Result(s)

within Hisashi Tsurumi Remove this filter Internal Medicine Remove this filter

and

  1. Article

    Open Access

    Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling

    Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) is a diagnosis of exclusion, being the most common entity in mature T-cell neoplasms, and its molecular pathogenesis remains significantly unders...

    Yosaku Watatani, Yasuharu Sato, Hiroaki Miyoshi, Kana Sakamoto, Kenji Nishida… in Leukemia (2019)

    Download PDF (2148 KB) View Article

  2. Article

    Open Access

    Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy

    We previously reported that oral ingestion of polaprezinc, a zinc-L-carnosine, suspended in sodium alginate solution prevents oral mucositis in patients receiving radiotherapy or high-dose chemotherapy. In the...

    Hiroko Hayashi, Ryo Kobayashi, Akio Suzuki, Yuto Yamada… in Medical Oncology (2016)

    Download PDF (460 KB) View Article

  3. No Access

    Article

    Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2

    The aim of this study was to assess the effects of acyclic retinoid (ACR) and vitamin K2 (VK2) in HL-60 cells.

    Junichi Kitagawa, Takeshi Hara… in Journal of Cancer Research and Clinical On… (2011)

  4. No Access

    Article

    Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma

    We previously described the effectiveness of the THP-COP regimen comprising cyclophosphamide, pirarubicin (tetrahydropyranyl adriamycin; THP), vincristine and prednisolone in patients with diffuse large B-cell...

    Takeshi Hara, Hisashi Tsurumi, Naoe Goto… in Journal of Cancer Research and Clinical On… (2010)

  5. No Access

    Article

    Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP

    We previously reported that serum concentrations of soluble Fas (sFas) predict the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) after treatment with CHOP but without rituximab (R). H...

    Takeshi Hara, Hisashi Tsurumi, Naoe Goto… in Journal of Cancer Research and Clinical On… (2009)

  6. No Access

    Article

    Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)

    The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).

    Jun-ichi Kitagawa, Takeshi Hara… in Journal of Cancer Research and Clinical On… (2009)

  7. No Access

    Article

    Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide

    To evaluate the efficacy and safety of a novel low dose chemotherapy as a remission induction regimen for elderly de novo AML patients ineligible for intensive chemotherapy.

    Hisashi Tsurumi, Nobuhiro Kanemura… in Journal of Cancer Research and Clinical On… (2007)

  8. No Access

    Article

    Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index

    The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin’s lymphoma (NHL).

    Hideko Goto, Hisashi Tsurumi, Masao Takemura… in Journal of Cancer Research and Clinical On… (2005)

  9. No Access

    Article

    Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma

    To compare the efficacy and safety of a biweekly CHOP regimen consisting of cyclophosphamide (CPA), doxorubicin (DOX), vincristine (VCR), and prednisolone (PSL) and those of a biweekly THP-COP regimen contain...

    Hisashi Tsurumi, Toshiki Yamada… in Journal of Cancer Research and Clinical On… (2004)

  10. No Access

    Article

    Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A

    We investigated whether immunosuppressive therapy using methylprednisolone (mPSL) with or without cyclosporin A (CsA) could benefit patients with myelodysplastic syndrome (MDS). Eligibility criteria for this s...

    Toshiki Yamada, Hisashi Tsurumi… in Journal of Cancer Research and Clinical On… (2003)